Daily Medication Pearl: Atogepant (Qulipta) for Episodic Migraine
Atogepant is indicated for the preventive treatment of episodic migraine in adults.
Medication Pearl of the Day: Atogepant (Qulipta)
Indication: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.
- Dosing: The recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food. Severe renal impairment or end-stage renal disease take 10 mg once daily.
- Dosage form: Tablets 10 mg, 30 mg, and 60 mg
- Adverse events (AEs): The most common AEs (at least 4% and greater than placebo) are nausea, constipation, and fatigue.
- Mechanism of action: Atogepant is a CGRP receptor antagonist.
- Manufacturer: AbbVie